Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Pertuzumab Plus Trastuzumab for Treatment-Refractory HER2-Amplified Metastatic Colorectal Cancer: Comparison of the MyPathway Trial With a Real-World External Control Arm

Pertuzumab Plus Trastuzumab for Treatment-Refractory HER2-Amplified Metastatic Colorectal Cancer:... PURPOSEWe compared overall survival (OS) in patients with human epidermal growth factor receptor 2 (HER2)–amplified, treatment-refractory metastatic colorectal cancer (mCRC) receiving pertuzumab plus trastuzumab (PER-HER) in the phase IIa MyPathway multibasket study (ClinicalTrials.gov identifier: NCT02091141) with OS in those receiving routine clinical care in an electronic health record–derived external control arm.METHODSA noninterventional study was conducted using patient-level data from MyPathway participants receiving PER-HER and real-world patients with HER2-amplified treatment-refractory mCRC receiving routine clinical care. This study used a deidentified US-based clinico-genomic database (CGDB). For patients in the CGDB who met study eligibility criteria at multiple index dates (treatment initiation dates in the treatment-refractory setting), all eligible index dates were used for the analysis. Standardized mortality ratio weighting on the basis of propensity score derived a pseudopopulation (postweighting population) balancing key prognostic variables between arms. Multivariate Cox proportional hazards models were used for estimation of the hazard ratio (HR) in the primary OS analysis. A series of sensitivity analyses were conducted to investigate the robustness and consistency of the primary analysis.RESULTSThe PER-HER arm comprised 57 patients enrolled in the MyPathway study by August 1, 2017 (data cutoff); the external control arm comprised 18 patients (27 index dates) with HER2-amplified mCRC who met the major MyPathway eligibility criteria in CGDB collected between 2011 and 2019. The estimated HR for OS from the multivariate Cox proportional hazards model in the postweighting population was 0.729 (95% CI, 0.184 to 3.900). The results of sensitivity analyses were consistent with the primary analysis in terms of the point estimate of HR.CONCLUSIONDespite a small sample size, these findings suggest that PER-HER could have a potential OS benefit for this population. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JCO: Clinical Cancer Informatics Wolters Kluwer Health

Pertuzumab Plus Trastuzumab for Treatment-Refractory HER2-Amplified Metastatic Colorectal Cancer: Comparison of the MyPathway Trial With a Real-World External Control Arm

Download PDF
10 pages

Loading next page...
 
/lp/wolters-kluwer-health/pertuzumab-plus-trastuzumab-for-treatment-refractory-her2-amplified-kfMaI7qUwk
Publisher
Wolters Kluwer Health
Copyright
© 2022 by American Society of Clinical Oncology
eISSN
2473-4276
DOI
10.1200/cci.22.00022
Publisher site
See Article on Publisher Site

Abstract

PURPOSEWe compared overall survival (OS) in patients with human epidermal growth factor receptor 2 (HER2)–amplified, treatment-refractory metastatic colorectal cancer (mCRC) receiving pertuzumab plus trastuzumab (PER-HER) in the phase IIa MyPathway multibasket study (ClinicalTrials.gov identifier: NCT02091141) with OS in those receiving routine clinical care in an electronic health record–derived external control arm.METHODSA noninterventional study was conducted using patient-level data from MyPathway participants receiving PER-HER and real-world patients with HER2-amplified treatment-refractory mCRC receiving routine clinical care. This study used a deidentified US-based clinico-genomic database (CGDB). For patients in the CGDB who met study eligibility criteria at multiple index dates (treatment initiation dates in the treatment-refractory setting), all eligible index dates were used for the analysis. Standardized mortality ratio weighting on the basis of propensity score derived a pseudopopulation (postweighting population) balancing key prognostic variables between arms. Multivariate Cox proportional hazards models were used for estimation of the hazard ratio (HR) in the primary OS analysis. A series of sensitivity analyses were conducted to investigate the robustness and consistency of the primary analysis.RESULTSThe PER-HER arm comprised 57 patients enrolled in the MyPathway study by August 1, 2017 (data cutoff); the external control arm comprised 18 patients (27 index dates) with HER2-amplified mCRC who met the major MyPathway eligibility criteria in CGDB collected between 2011 and 2019. The estimated HR for OS from the multivariate Cox proportional hazards model in the postweighting population was 0.729 (95% CI, 0.184 to 3.900). The results of sensitivity analyses were consistent with the primary analysis in terms of the point estimate of HR.CONCLUSIONDespite a small sample size, these findings suggest that PER-HER could have a potential OS benefit for this population.

Journal

JCO: Clinical Cancer Informatics – Wolters Kluwer Health

Published: May 1, 2022

References

  • Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
    Bray, F; Ferlay, J; Soerjomataram, I
  • A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer
    Goldberg, RM; Sargent, DJ; Morton, RF
  • FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study
    Tournigand, C; Andre, T; Achille, E
  • Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild‐type advanced or metastatic colorectal cancer: A randomized clinical trial
    Venook, AP; Niedzwiecki, D; Lenz, HJ
  • FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: Updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
    Cremolini, C; Loupakis, F; Antoniotti, C
  • FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial
    Heinemann, V; von Weikersthal, LF; Decker, T
  • Metastatic colorectal cancer: Therapeutic options for treating refractory disease
    Parmar, A; Chan, KKW; Ko, YJ
  • Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers
    Marx, AH; Burandt, EC; Choschzick, M
  • HER2 status in colorectal cancer: Its clinical significance and the relationship between HER2 gene amplification and expression
    Seo, AN; Kwak, Y; Kim, DW
  • Prognostic and predictive value of HER2 amplification in patients with metastatic colorectal cancer
    Sawada, K; Nakamura, Y; Yamanaka, T
  • Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial
    Sartore-Bianchi, A; Trusolino, L; Martino, C
  • HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer
    Raghav, KPS; Overman, MJ; Yu, R
  • Pertuzumab and trastuzumab for HER2-amplified metastatic colorectal cancer: An updated report from MyPathway, a multicentre, open-label, phase 2a multiple basket study
    Meric-Bernstam, F; Hurwitz, H; Raghav, KPS
  • Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: A phase 2 trial
    Nakamura, Y; Okamoto, W; Kato, T
  • Real-world effectiveness to support regulatory decision-making for medicines: Considerations for external control arms
    Burcu, M; Dreyer, NA; Franklin, JM
  • Association of patient characteristics and tumor genomics with clinical outcomes among patients with non-small cell lung cancer using a clinicogenomic database
    Singal, G; Miller, PG; Agarwala, V
  • Simulation-based evaluation of index date selection methods with external controls
    Gower-Page, C; Li, C; Schröder, C
  • How to choose a time zero for patients in external control arms
    Backenroth, D
  • Building external control arms from patient-level electronic health record data to replicate the randomized IMblaze370 control arm in metastatic colorectal cancer
    Schröder, C; Lawrence, M; Li, C
  • Using electronic health records to derive control arms for early phase single-arm lung cancer trials: Proof-of-concept in randomized controlled trials
    Carrigan, G; Whipple, S; Capra, WB